In vivo genome-wide CRISPR screening identifies CITED2 as a driver of prostate cancer bone metastasis. Arriaga JM, Ronaldson-Bouchard K, Picech F, Nunes de Almeida F, et al. Oncogene 2024 Mar 7. doi: 10.1038/s41388-024-02995.

Read + Share

Amedeo Smart

Independent Medical Education

Arriaga JM, Ronaldson-Bouchard K, Picech F, Nunes de Almeida F, et al. In vivo genome-wide CRISPR screening identifies CITED2 as a driver of prostate cancer bone metastasis. Oncogene 2024 Mar 7. doi: 10.1038/s41388-024-02995.
PMID: 38454137